Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.915 USD | +3.12% | +6.48% | +11.74% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.74% | 87.8M | |
+33.69% | 704B | |
+28.55% | 577B | |
-5.19% | 348B | |
+18.02% | 327B | |
+4.29% | 288B | |
+15.00% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.74% | 147B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HOOKIPA Pharma : Truist Starts HOOKIPA Pharma at Buy With $21 Price Target